Abstract
Mineralocorticoid receptor (MR) and its ligand aldosterone play a central role in controlling blood pressure by promoting sodium reabsorption in the kidney. Coregulators are recruited to regulate the activation of steroid hormone receptors. In our previous study, we identified several new candidates for MR coregulators through liquid chromatography-tandem mass spectrometry analysis using a biochemical approach. Lysine-specific demethylase 1 (LSD1) was identified as a candidate. The relationship between LSD1 and salt-sensitive hypertension has been reported; however, the role of MR in this condition is largely unknown. Here, we investigated the functions of LSD1 as a coregulator of MR. First, a coimmunoprecipitation assay using HEK293F cells showed specific interactions between MR and LSD1. A chromatin immunoprecipitation study demonstrated LSD1 recruitment to the gene promoter of epithelial Na+ channel (ENaC), a target gene of MR. Reduced LSD1 expression by treatment with shRNA potentiated the hormonal activation of ENaC and serum/glucocorticoid-regulated kinase 1, another target gene of MR, indicating that LSD1 is a corepressor of MR. In an animal study, mice with kidney-specific LSD1 knockout (LSD1flox/floxKSP-Cre mice) developed hypertension after a high-salt diet without elevation of aldosterone levels, which was counteracted by cotreatment with spironolactone, an MR antagonist. In conclusion, our in vitro and in vivo studies demonstrated that LSD1 is a newly identified corepressor of MR.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Shibata H, Itoh H. Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension. Am J Hypertens. 2012;25:514–23.
Morimoto S, Ichihara A. Management of primary aldosteronism and mineralocorticoid receptor-associated hypertension. Hypertens Res. 2020;43:744–53.
Hayashi T, Shibata H, Kurihara I, Yokota K, Mitsuishi Y, Ohashi K, et al. High glucose stimulates mineralocorticoid receptor transcriptional activity through the protein kinase C β signaling. Int Heart J. 2017;58:794–802.
Mitsuishi Y, Shibata H, Kurihara I, Kobayashi S, Yokota K, Murai-Takeda A, et al. Epidermal growth factor receptor/extracellular signal-regulated kinase pathway enhances mineralocorticoid receptor transcriptional activity through protein stabilization. Mol Cell Endocrinol. 2018;473:89–99.
Shibata S, Nagase M, Yoshida S, Kawarazaki W, Kurihara H, Tanaka H, et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med. 2008;14:1370–6.
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N. Engl J Med. 1999;341:709–17.
Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl J Med. 2003;348:1309–21.
Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl J Med. 2011;364:11–21.
Nishimoto M, Ohtsu H, Marumo T, Kawarazaki W, Ayuzawa N, Ueda K, et al. Mineralocorticoid receptor blockade suppresses dietary salt-induced ACEI/ARB-resistant albuminuria in non-diabetic hypertension: a sub-analysis of evaluate study. Hypertens Res. 2019;42:514–21.
Yokota K, Shibata H, Kurihara I, Kobayashi S, Murai-Takeda A, Itoh H. CASZ1b is a novel transcriptional corepressor of mineralocorticoid receptor. Hypertens Res. 2021;44:407–16.
Pojoga LH, Williams JS, Yao TM, Kumar A, Raffetto JD, do Nascimento GR, et al. Histone demethylase LSD1 deficiency during high-salt diet is associated with enhanced vascular contraction, altered NO-cGMP relaxation pathway, and hypertension. Am J Physiol Heart Circ Physiol. 2011;301:H1862–71.
Williams JS, Chamarthi B, Goodarzi MO, Pojoga LH, Sun B, Garza AE, et al. Lysine-specific demethylase 1: an epigenetic regulator of salt-sensitive hypertension. Am J Hypertens. 2012;25:812–7.
Krug AW, Tille E, Sun B, Pojoga L, Williams J, Chamarthi B, et al. Lysine-specific demethylase-1 modifies the age effect on blood pressure sensitivity to dietary salt intake. Age. 2013;35:1809–20.
Treesaranuwattana T, Wong KYH, Brooks DL, Tay CS, Williams GH, Williams JS, et al. Lysine-specific demethylase-1 deficiency increases agonist signaling via the mineralocorticoid receptor. Hypertension. 2020;75:1045–53.
Yokota K, Shibata H, Kurihara I, Kobayashi S, Suda N, Murai-Takeda A, et al. Coactivation of the N-terminal transactivation of mineralocorticoid receptor by Ubc9. J Biol Chem. 2007;282:1998–2010.
Murai-Takeda A, Shibata H, Kurihara I, Kobayashi S, Yokota K, Suda N, et al. NF-YC functions as a corepressor of agonist-bound mineralocorticoid receptor. J Biol Chem. 2010;285:8084–93.
Levy D, Ehret GB, Rice K, Verwoert GC, Launer LJ, Dehghan A, et al. Genome-wide association study of blood pressure and hypertension. Nat Genet. 2009;41:677–87.
Takeuchi F, Isono M, Katsuya T, Yamamoto K, Yokota M, Sugiyama T, et al. Blood pressure and hypertension are associated with 7 loci in the Japanese population. Circulation. 2010;121:2302–9.
Ho JE, Levy D, Rose L, Johnson AD, Ridker PM, Chasman DI. Discovery and replication of novel blood pressure genetic loci in the Women’s Genome Health Study. J Hypertens. 2011;29:62–9.
Kato N, Takeuchi F, Tabara Y, Kelly TN, Go MJ, Sim X, et al. Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in east Asians. Nat Genet. 2011;43:531–8.
Forneris F, Battaglioli E, Mattevi A, Binda C. New roles of flavoproteins in molecular cell biology: histone demethylase LSD1 and chromatin. FEBS J. 2009;276:4304–12.
Kooistra SM, Helin K. Molecular mechanisms and potential functions of histone demethylases. Nat Rev Mol Cell Biol. 2012;13:297–311.
Metzger E, Wissmann M, Yin N, Müller JM, Schneider R, Peters AH, et al. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature. 2005;437:436–9.
Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 2004;119:941–53.
Wang Y, Zhang H, Chen Y, Sun Y, Yang F, Yu W, et al. LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell. 2009;138:660–72.
Wissmann M, Yin N, Müller JM, Greschik H, Fodor BD, Jenuwein T, et al. Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression. Nat Cell Biol. 2007;9:347–53.
Metzger E, Imhof A, Patel D, Kahl P, Hoffmeyer K, Friedrichs N, et al. Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at histone H3K4. Nature. 2010;464:792–6.
Cai C, He HH, Chen S, Coleman I, Wang H, Fang Z, et al. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell. 2011;20:457–71.
Cai C, He HH, Gao S, Chen S, Yu Z, Gao Y, et al. Lysine-specific demethylase 1 has dual functions as a major regulator of androgen receptor transcriptional activity. Cell Rep. 2014;9:1618–27.
Yang S, Zhang J, Zhang Y, Wan X, Zhang C, Huang X, et al. KDM1A triggers androgen-induced miRNA transcription via H3K4me2 demethylation and DNA oxidation. Prostate. 2015;75:936–46.
Garcia-Bassets I, Kwon YS, Telese F, Prefontaine GG, Hutt KR, Cheng CS, et al. Histone methylation-dependent mechanisms impose ligand dependency for gene activation by nuclear receptors. Cell. 2007;128:505–18.
Perillo B, Ombra MN, Bertoni A, Cuozzo C, Sacchetti S, Sasso A, et al. DNA oxidation as triggered by H3K9me2 demethylation drives estrogen-induced gene expression. Science. 2008;319:202–6.
Nair SS, Nair BC, Cortez V, Chakravarty D, Metzger E, Schüle R, et al. PELP1 is a reader of histone H3 methylation that facilitates oestrogen receptor-alpha target gene activation by regulating lysine demethylase 1 specificity. EMBO Rep. 2010;11:438–44.
Bennesch MA, Segala G, Wider D, Picard D. LSD1 engages a corepressor complex for the activation of the estrogen receptor α by estrogen and cAMP. Nucleic Acids Res. 2016;44:8655–70.
Clark EA, Wu F, Chen Y, Kang P, Kaiser UB, Fang R, et al. GR and LSD1/KDM1A-targeted gene activation requires selective H3K4me2 demethylation at enhancers. Cell Rep. 2019;27:3522–32.e3.
Shibata S, Mu S, Kawarazaki H, Muraoka K, Ishizawa K, Yoshida S, et al. Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway. J Clin Invest. 2011;121:3233–43.
Shao X, Somlo S, Igarashi P. Epithelial-specific Cre/lox recombination in the developing kidney and genitourinary tract. J Am Soc Nephrol. 2002;13:1837–46.
Guan Y, Liu H, Ma Z, Li SY, Park J, Sheng X, et al. Dnmt3a and Dnmt3b-decommissioned fetal enhancers are linked to kidney disease. J Am Soc Nephrol. 2020;31:765–82.
Sato T, Courbebaisse M, Ide N, Fan Y, Hanai JI, Kaludjerovic J, et al. Parathyroid hormone controls paracellular Ca2+ transport in the thick ascending limb by regulating the tight-junction protein Claudin14. Proc Natl Acad Sci USA. 2017;114:E3344–53.
Nakamura T, Kurihara I, Kobayashi S, Yokota K, Murai-Takeda A, Mitsuishi Y, et al. Intestinal mineralocorticoid receptor contributes to epithelial sodium channel-mediated intestinal sodium absorption and blood pressure regulation. J Am Heart Assoc. 2018;7:e008259.
Huang Y, Ting PY, Yao TM, Homma T, Brooks D, Katayama Rangel I, et al. Histone demethylase LSD1 deficiency and biological sex: impact on blood pressure and aldosterone production. J Endocrinol. 2019;240:111–22.
Acknowledgements
We would like to thank Editage (www.editage.com) for English language editing.
Funding
This research was supported by JSPS KAKENHI (grant number: 18K08250) (to S.K.) and the Smoking Research Foundation (to H.I.) and partly supported by JSPS KAKENHI (Grant number: 19K08713) (to I.K.), JSPS KAKENHI (Grant number: 18K16007) (to A.M.), JSPS KAKENHI (Grant number: 19K17992) (to Y.M.), JSPS KAKENHI (Grant number: 21K08236) (to K.Y.), JSPS KAKENHI (Grant number: 20K17256) (to M.K.), and the Research Committee on Disorders of Adrenal Hormones, a Grant-in-Aid from the Ministry of Health, Labour and Welfare of Japan (Nanjiseisikkanseisakukenkyujigyo [20FC1020]) (to I.K.)
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that there are no conflicts of interest that could be perceived as prejudicing the impartiality of the research reported.
Ethical approval
All animal procedures were approved by the institutional review board of the Animal Care and Use Committee and were conducted in compliance with the animal experimentation guidelines of the Keio University School of Medicine.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Kohata, N., Kurihara, I., Yokota, K. et al. Lysine-specific demethylase 1 as a corepressor of mineralocorticoid receptor. Hypertens Res 45, 641–649 (2022). https://doi.org/10.1038/s41440-022-00859-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41440-022-00859-7
Keywords
This article is cited by
-
2023 update and perspectives
Hypertension Research (2024)
-
CASZ1: a promising factor modulating aldosterone biosynthesis and mineralocorticoid receptor activity
Hypertension Research (2023)